Use of β-Blockers in Pulmonary Hypertension

Frédéric Perros*, Frances S. De Man, Harm J. Bogaard, Fabrice Antigny, Gérald Simonneau, Sébastien Bonnet, Steeve Provencher, Nazzareno Galiè, Marc Humbert

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Contrasting with the major attention that left heart failure has received, right heart failure remains understudied both at the preclinical and clinical levels. However, right ventricle failure is a major predictor of outcomes in patients with precapillary pulmonary hypertension because of pulmonary arterial hypertension, and in patients with postcapillary pulmonary hypertension because of left heart disease. In pulmonary hypertension, the status of the right ventricle is one of the most important predictors of both morbidity and mortality. Paradoxically, there are currently no approved therapies targeting the right ventricle in pulmonary hypertension. By analogy with the key role of β-blockers in the management of left heart failure, some authors have proposed to use these agents to support the right ventricle function in pulmonary hypertension. In this review, we summarize the current knowledge on the use of β-blockers in pulmonary hypertension.

Original languageEnglish
Article numbere003703
JournalCirculation: Heart Failure
Volume10
Issue number4
DOIs
Publication statusPublished - 1 Apr 2017

Cite this